Maryland Medicaid participants can now more easily access cell and gene therapies for sickle cell disease under Maryland’s participation in the federal Cell and Gene Therapy (CGT) Access Model. Participation in the CGT Access Model ensures better pricing in Maryland for high-cost medications, which helps to reduce costs and strengthen support services for patients...
Read More »


























